Long‐term Results of a Randomized, Double‐blind, and Placebo‐controlled Phase III Trial: Endostar (rh‐endostatin) Versus Placebo in Combination with Vinorelbine and Cisplatin in Advanced Non‐small Cell Lung Cancer
Yan Sun,Jin Wan Wang,Yong Yu Liu,Qi Tao Yu,Yi Ping Zhang,Kai Li,Li Yan Xu,Su Xia Luo,Feng Zhan Qin,Zheng Tang Chen,Wen Chao Liu,Qing Hua Zhou,Qiang Chen,Ke Jun Nan,Xiao Qing Liu,Wei Liu,Hou Jie Liang,Hui Shan Lu,Xiu Wen Wang,Jie Jun Wang,Shu Ping Song,Yuan Rong Tu,Jing Min Zhou,Wei Lian Li,Chen Yao
DOI: https://doi.org/10.1111/1759-7714.12050
IF: 3.223
2013-01-01
Thoracic Cancer
Abstract:Background:Phase II-III trials in patients with untreated and previously treated locally advanced or non-small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum-based chemotherapy (NP regimen) with tolerable adverse effects.MethodsFour hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles.Results:Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001).Conclusion:Long-term follow-up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.